

U.S. Ser. No. 09/868,889

Page 2 of 17


AMENDMENTS TO THE CLAIMS

This listing of Claims will replace all prior versions, and listings, of Claims in the application:

LISTING OF CLAIMS

## 1. (Currently Amended)

A compound having the formula



wherein

n is an integer from 0 to 4;

R<sub>1</sub> is C<sub>1</sub> to C<sub>6</sub> alkyl or C<sub>3</sub> cycloalkyl;

R<sub>2</sub> and R<sub>3</sub> are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons, at least one of R<sub>2</sub> and R<sub>3</sub> being other than hydrogen;

~~R<sub>4</sub> is a heteroaromatic moiety which may be substituted or unsubstituted and is linked to (CH<sub>2</sub>)<sub>n</sub> via a nitrogen atom or a carbon atom; an amine (NR'R''), including those in which the amine is derived from an alpha amino acid of either natural (L) or unnatural (D) stereochemistry; an acylsulphonamide (CONHSO<sub>2</sub>R'), or a carboxylic acid amide (CONR'R'') in which R' and R'' are the same or different and are independently selected from hydrogen, alkyl, aryl, and heteroaryl substituted or unsubstituted with the proviso that when n equals zero (n=0), then R<sub>4</sub> can only be a carboxylic acid amide or an acylsulphonamide;~~


U.S. Ser. No. 09/868,889

Page 3 of 17

$R_5$  is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (where in  $R_5 = H$ );

including all stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof.

2. (Previously Presented) A compound as defined in Claim 1 wherein  $R_4$  is a carboxylic acid amide ( $\text{CONR}'\text{R}''$ ) in which the amine portion of the carboxylic amide can be derived from an achiral or a L or D alpha amino acid such as when the general structure  $-\text{CONR}'\text{R}''$  can be represented by



and  $R'$ ,  $R''$ ,  $R'''$ ,  $R''''$ , are the same or different and are independently selected from hydrogen, alkyl, aryl and heteroaryl, substituted or unsubstituted, and  $R^*$  may be hydrogen, alkyl, aryl and heteroaryl, substituted or unsubstituted, and may also be any of the side chains found in the naturally occurring alpha-amino acids.

3. (Original) The compound as defined in Claim 2 where  $R'$  and  $R^*$  are connected to form a 4 to 8-membered ring.

4. (Original) The compound as defined in Claim 2 where  $R'$  and  $R^*$  comprise consecutive  $-(\text{CH}_2)-$  groups to form proline or homoproline.

U.S. Ser. No. 09/868,889

Page 4 of 17


5. (Original) The compound as defined in Claim 1 where  $n$  is 0, 1, or 2.
6. (Original) The compound as defined in Claim 1 wherein  $R_2$  and  $R_3$  are each independently halogen.
7. (Original) The compound as defined in Claim 1 wherein  $R_2$  and  $R_3$  are each independently an alkyl group.
8. (Original) The compound as defined in Claim 1 wherein one of  $R_2$  and  $R_3$  is halogen and the other is an alkyl group.
9. (Original) The compound as defined in Claim 1 wherein one of  $R_2$  and  $R_3$  is halogen and the other is hydrogen.
10. (Original) The compound as defined in Claim 1 wherein  $R_2$  and  $R_3$  is alkyl and the other is hydrogen.
11. (Original) The compound as defined in Claim 1 wherein  $R_2$  and  $R_3$  are independently Cl, Br, methyl or ethyl.
12. (Original) The compound as defined in Claim 1 wherein  $R_1$  is isopropyl.
13. (Cancelled).
14. (Original) The compound as defined in Claim 1 wherein  $R_5$  is hydrogen.

U.S. Ser. No. 09/868,889









Page 5 of 17

Claims 15.-16. (Cancelled)

17. (Original) The compound as defined in Claim 1 which is in the table below,




R=



U.S. Ser. No. 09/868,889

Page 6 of 17

and the compounds indicated in the table below



-NR'R''	Formula
3-(AMINOMETHYL)PYRIDINE	C <sub>23</sub> H <sub>22</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-(2-AMINOETHYL)PYRIDINE	C <sub>24</sub> H <sub>24</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
-NR'R''	Formula
3-(2-AMINOETHYL)PYRIDINE	C <sub>24</sub> H <sub>24</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-(AMINOMETHYL)PYRIDINE	C <sub>24</sub> H <sub>30</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
4-(AMINOMETHYL)PYRIDINE	C <sub>24</sub> H <sub>30</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
1-(4-METHOXYPHENYL)PIPERAZINE DIHYDROCHLORIDE	C <sub>28</sub> H <sub>32</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
1-(2-FLUOROPHENYL)PIPERAZINE	C <sub>34</sub> H <sub>32</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-(2-(AMINOMETHYL)PHENYLTHIO)BENZYL ALCOHOL	C <sub>31</sub> H <sub>28</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>4</sub> S
2-(1-CYCLOHEXYNYL)ETHYLAMINE	C <sub>26</sub> H <sub>29</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-AMINOINDAN	C <sub>28</sub> H <sub>25</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-AMINOMETHYLBENZODIOXAN	C <sub>28</sub> H <sub>25</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
3-PHENYL-1-PROPYLAMINE	C <sub>28</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-(P-TOLYL)ETHYLAMINE	C <sub>28</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
1-(3-AMINOPROPYL)-2-PYRROLIDINONE	C <sub>24</sub> H <sub>28</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>4</sub>
BETA-ALANINE 4-METHOXY-BETA-NAPHTHYLAMIDE	C <sub>31</sub> H <sub>30</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
2-CHLOROBENZYLAMINE	C <sub>24</sub> H <sub>22</sub> Br <sub>2</sub> ClN <sub>2</sub> O <sub>3</sub>
2-AMINOMETHYL-3-CHLORODIPHENYLETHER	C <sub>30</sub> H <sub>26</sub> Br <sub>2</sub> ClN <sub>2</sub> O <sub>4</sub>
DL-ALPHA-AMINO-EPSILON-CAPROLACTAM	C <sub>23</sub> H <sub>28</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>4</sub>
L-PHENYLALANINOL	C <sub>28</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>4</sub>
4-(1,2,3-THIAZOL-4-YL)BENZYLAMINE	C <sub>28</sub> H <sub>28</sub> Br <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S
2-AMINOMETHYLTHIOPHENE	C <sub>22</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub> S
1-(1-NAPHTHYL)ETHYLAMINE	C <sub>28</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
3-CHLORO-4-METHYL BENZYLAMINE	C <sub>28</sub> H <sub>24</sub> Br <sub>2</sub> ClN <sub>2</sub> O <sub>3</sub>
TETRAHYDROFURFURYLAMINE	C <sub>22</sub> H <sub>28</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>4</sub>
2,4-DICHLOROPHENETHYLAMINE	C <sub>25</sub> H <sub>23</sub> Br <sub>2</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
ETHYL 4-AMINO-1-PIPERIDINECARBOXYLATE	C <sub>25</sub> H <sub>30</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
2,6-DIFLUOROBENZYLAMINE	C <sub>24</sub> H <sub>21</sub> Br <sub>2</sub> F <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-IODOBENZYLAMINE	C <sub>24</sub> H <sub>22</sub> Br <sub>2</sub> I <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-METHYLBENZYLAMINE	C <sub>25</sub> H <sub>26</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
BENZYLAMINE	C <sub>24</sub> H <sub>28</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
3-METHYLBENZYLAMINE	C <sub>25</sub> H <sub>26</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-METHOXYPHENETHYLAMINE	C <sub>28</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>4</sub>
3-METHOXYPHENETHYLAMINE	C <sub>28</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>4</sub>
2-ETHOXYBENZYLAMINE	C <sub>28</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>4</sub>
(R)-(-)-1-CYCLO-HEXYLETHYLAMINE	C <sub>25</sub> H <sub>31</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
4-METHOXYPHENETHYLAMINE	C <sub>28</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>4</sub>
2-FLUOROBENZYLAMINE	C <sub>24</sub> H <sub>22</sub> Br <sub>2</sub> F <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-CHLORO-6-METHYLBENZYLAMINE	C <sub>25</sub> H <sub>24</sub> Br <sub>2</sub> ClN <sub>2</sub> O <sub>3</sub>
4-CHLOROBENZYLAMINE	C <sub>24</sub> H <sub>22</sub> Br <sub>2</sub> ClN <sub>2</sub> O <sub>3</sub>

U.S. Ser. No. 09/868,889

Page 7 of 17

BETA-METHYLPHENETHYLAMINE	C26H27Br2NO3
1,1-DI(P-ANISYL)METHYLAMINE	C32H31Br2NO6
MAYBRIDGE BTB 12133	C27H29Br2NO6
DL-2-AMINO-1-PENTANOL	C22H27Br2NO4
L-PHENYLALANINE P-NITROANILIDE	C32H29Br2N3O6
ETHYL 3-AMINOBUTYRATE	C23H27Br2NO5
(1S,2R)(+)-2-AMINO-1,2-DIPHENYLETHANOL	C31H29Br2NO4
2-FLUOROPHENETHYLAMINE	C25H24Br2FNO3
2-ETHYLHEXYLAMINE	C26H33Br2NO3
3-FLUOROPHENETHYLAMINE	C25H24Br2FNO3
(1S,2S)(+)-2-AMINO-3-METHOXY-1-PHENYL-1-PROPANOL	C27H29Br2NO5
NONYLAMINE	C26H35Br2NO3
2,5-DICHLOROBENZYLAMINE	C24H21Br2Cl2NO3
2-METHYLCYCLOHEXYLAMINE	C24H29Br2NO3
3-METHYLCYCLOHEXYLAMINE	C24H29Br2NO3
3-N-PROPOXYPROPYLAMINE	C23H29Br2NO4
2,3-DIMETHYLBENZYLAMINE	C25H27Br2NO3
3-CHLOROBENZYLAMINE	C24H22Br2ClNO3
4-TERT-BUTYLCYCLOHEXYLAMINE	C27H35Br2NO3
-NR'R"	Formula
(1S,2S)(+)-THIOMICAMINE	C27H29Br2NO5S
2,4-DIMETHYLBENZYLAMINE	C26H27Br2NO3
2-AMINOETHYL PHENYL SULFIDE	C25H25Br2NO3S
PHENETHYLAMINE	C25H25Br2NO3
TYRAMINE	C25H25Br2NO4
L-TYROSINE METHYL ESTER	C27H27Br2NO6
BENZHYDRYLAMINE	C30H27Br2NO3
4-METHOXYBENZYLAMINE	C25H25Br2NO4
2,3-DICHLOROBENZYLAMINE	C24H21Br2Cl2NO3
GLYCINE N-BUTYL ESTER HYDROCHLORIDE	C23H27Br2NO5
D-(-)-ALPHA-PHENYLGLYCINE ETHYL ESTER HYDROCHLORIDE	C27H27Br2NO5
4-CHLORO-2-FLUOROBENZYLAMINE HYDROCHLORIDE	C24H21Br2ClFNO3
TRANS-2-PHENYLOXYCLOPROPYLAMINE HYDROCHLORIDE	C26H25Br2NO3
ETHYL 4-AMINOBUTYRATE HYDROCHLORIDE	C23H27Br2NO5
DL-HOMOCYSTEINE THIOACTONE HYDROCHLORIDE	C21H21Br2NO4S
4-NITROBENZYLAMINE HYDROCHLORIDE	C24H22Br2N2O5
NORPHENYLEPHRINE HYDROCHLORIDE	C25H25Br2NO5
GLYCINE ETHYL ESTER HYDROCHLORIDE	C21H23Br2NO5
DL-ALANINE ETHYL ESTER HYDROCHLORIDE	C22H25Br2NO5
SARCOSINE ETHYL ESTER HYDROCHLORIDE	C22H25Br2NO5
4-NITRO-N-PROPYLBENZYLAMINE HYDROCHLORIDE	C27H28Br2N2O5
PIPERIDINE	C22H25Br2NO3
2-METHYLPYRROLIDINE	C23H27Br2NO3
8-(HYDROXYMETHYL)-PIPERIDINE	C23H27Br2NO4
1,2,3,4-TETRAHYDROISOQUINOLINE	C26H25Br2NO3
2-ETHYLPYRROLIDINE	C24H26Br2NO3
3,4-DICHLORO-N-ETHYLBENZYLAMINE	C26H25Br2Cl2NO3
2-METHYLPYRROLIDINE	C22H25Br2NO3
N-ETHYL-N-PROPYLAMINE	C22H27Br2NO3
4-METHYLPYRROLIDINE	C23H27Br2NO3
(S)(+)-2-(METHOXYMETHYL)PYRROLIDINE	C23H27Br2NO4

U.S. Ser. No. 09/868,889

Page 8 of 17

N-BENZYLETHANOLAMINE	C28H27Br2NO4
DIBENZYLAMINE	C31H29Br2NO3
4-BENZYL-4-HYDROXYPIPERIDINE	C28H31Br2NO4
(R)-(-)-2-BENZYLAMINO-1-BUTANOL	C28H31Br2NO4
N-(N-ETHYLAMINOACETYL)-2,6-DIMETHYLANILINE	C28H32Br2N2O4
N-ETHYL-O-METHOXYBENZYLAMINE	C27H29Br2NO4
MAYBRIDGE NRB 01961	C30H33Br2NO5
2-((N-ETHYLAMINO)METHYL)-4-NITROPHENOL	C26H26Br2N2O6
MAYBRIDGE SEW 01484	C31H29Br2NO4S
3-AZABICYCLO-[3.2.2]NONANE	C26H26Br2NO3
N-(2-METHOXY-ETHYL)ETHYLAMINE	C22H27Br2NO4

18. (Currently Amended) The compound as defined in Claim 1 which is

*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]valine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]leucine,  
*L*-S-Benzyl, N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]cysteine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]tyrosine,  
~~*L*-N-(2,2,5,7,8-Pentamethylethroman-6-sulfonyl),~~  
*N*-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]arginine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]aminobutyric acid,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]valine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]leucine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]proline,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]cysteine,  
*N*-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]glycine,  
*L*-N- $\alpha$ -[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]lysine,  
*D*-N- $\alpha$ -[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]lysine,  
*N*-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]aminoisobutyric acid,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylglycine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylglycine,  
*N*-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]sarcosine,  
*DL*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]- $\alpha$ -methylphenylalanine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]isoleucine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]methionine,  
~~*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]methionine,~~

U.S. Ser. No. 09/868,889

Page 9 of 17

*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylalanine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylalanine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]cyclohexylalanine,  
*L*-N- $\epsilon$ -(Benzyloxycarbonyl), N- $\alpha$ -[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzoyl]lysine,  
*D*-N- $\epsilon$ -(Benzyloxycarbonyl), N- $\alpha$ -[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-benzoyl]lysine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]homoserine,  
N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]glycine,  
N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]sarcosine,  
3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylformylimino diacetic acid,  
N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]- $\beta$ -alanine,  
N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]- $\beta$ -alanine,  
*D*-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]methionine,  
*L*-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]serine  
*D*-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]serine  
N-[3,5-Dichloro-4-(4-hydroxy-3-bromophenoxy)benzoyl]glycine  
N-[3,5-Dichloro-4-(4-hydroxy-3-methylphenoxy)benzoyl]glycine  
N-[3,5-Dichloro-4-(4-hydroxy-3-ethylphenoxy)benzoyl]glycine

19. (Original) The compound as defined in Claim 1 which is

*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]methionine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]methionine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]  $\alpha$ -methylalanine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]asparagine,  
*L*-Methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]alanine,  
*L*-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]alanine,  
*L*-Dimethyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate,  
*L*-Dimethyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate,  
*L*-(*O*-*tert*-butyl)methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate,




U.S. Ser. No. 09/868,889

Page 10 of 17

*L*-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamic acid,  
*L*-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]aspartic acid,  
*D*-di-*tert*-butyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamic acid,  
*L*-O-*tert*-Butyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamine,  
*L*-O-Benzyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]aspartic acid,  
*L*-O-*tert*-Butyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]asparagine,  
*L*-Methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]homoserine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]homoserine,  
*D*-Methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]homoserine,







and the compounds showed in the table below,



R	Mol Formula
L-Val	C <sub>22</sub> H <sub>25</sub> Br <sub>2</sub> NO <sub>5</sub>
L-Val	C <sub>22</sub> H <sub>25</sub> Br <sub>2</sub> NO <sub>5</sub>
L-Tyr	C <sub>26</sub> H <sub>25</sub> Br <sub>2</sub> NO <sub>6</sub>
	C <sub>23</sub> H <sub>27</sub> Br <sub>2</sub> NO <sub>5</sub>
	C <sub>27</sub> H <sub>27</sub> Br <sub>2</sub> NO <sub>5</sub> S

U.S. Ser. No. 09/868,889


Page 11 of 17

D-Leu	C <sub>23</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
D-Tyr	C <sub>26</sub> H <sub>25</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
D-Trp	C <sub>28</sub> H <sub>28</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
L-Arg	C <sub>23</sub> H <sub>28</sub> Br <sub>2</sub> N <sub>4</sub> O <sub>5</sub>
L-Abu	C <sub>21</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
	C <sub>20</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
	C <sub>20</sub> H <sub>21</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
L-Leu	C <sub>23</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
	C <sub>25</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
D-Pro	C <sub>22</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
L-Ile	C <sub>23</sub> H <sub>27</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
	C <sub>23</sub> H <sub>25</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
L-Phe	C <sub>26</sub> H <sub>25</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
L-Lys	C <sub>23</sub> H <sub>28</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
	C <sub>23</sub> H <sub>25</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
L-Pro	C <sub>22</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>
	C <sub>25</sub> H <sub>23</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>5</sub>

U.S. Ser. No. 09/868,889


Page 12 of 17

20. (Original) The compounds as defined in Claim 1 having the structures



or a pharmaceutically acceptable salt or ester(s) thereof.

21. (Original) The compounds as defined in Claim 1 having the structures




or a pharmaceutically acceptable salt or ester(s) thereof.

U.S. Ser. No. 09/868,889

Page 13 of 17

22. (Original) The compounds as defined in Claim 1 having the structures



wherein R<sub>1</sub>= isopropyl, methyl, ethyl; R<sub>2</sub> and R<sub>3</sub> may be independently selected from Br, Cl and Me; n=0 or 1; R\* may be hydrogen, alkyl, cycloalkyl, aryl and heteroaryl; \* denotes either D or L stereochemistry when R\* is not hydrogen; R<sub>5</sub> is hydrogen; and R' is selected from hydrogen, lower alkyl, especially ethyl and methyl.

23. - 26. (Cancelled)

27. (Original) A pharmaceutical composition comprising an effective amount of a compound according to Claim 1 or a pharmaceutically effective salt thereof, together with a pharmaceutically acceptable carrier.

28. (Cancelled)

29. (Previously Presented) A method to treat a skin disorder or disease selected from the group consisting of dermal atrophy, post surgical bruising caused by laser resurfacing, keloids, stria, cellulite, roughened skin, actinic skin damage, lichen planus, ichthyosis, acne, psoriasis, Dernier's diseases, eczema, atopic dermatitis, chloracne, pityriasis and skin scarring, said

U.S. Ser. No. 09/868,889

Page 14 of 17

method comprising the step of administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**